✷ Report Code: A03071 | Apr 2022 | Pages: 190 | ||
Tables: 118 | Charts: 56 |
|
The global Gynecological Cancer Drugs Market Size was valued at $11.6 billion in 2020 and is projected to reach $21.8 billion by 2030, growing at a CAGR of 6.5% from 2021 to 2030.
Gynecological Cancer refers to a group of cancers that affect the reproductive organs of a female such as an endometrium, uterus, peritoneum, ovary, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus. Cancer is a specific disorder that can cause abnormal cell growth in any part of the body. Cancer is named after the body part in which it originates, so gynecological cancer refers to a group of cancers that affect the reproductive organs of a female.
The COVID-19 pandemic has a negative impact on the gynecological cancer drugs market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - ovarian, vulvar cancer, cervical cancer, endometrium cancer, vaginal cancer, fallopian tube cancer and among others. Thus, the COVID-19 pandemic has impacted the gynecological cancer drugs market. However, the situation is expected to gradually improve.
The key factors that drive the Gynecological Cancer Drugs Market Growth are the rise in the incidence of gynecological cancers and an increase in investment from the government, public, &private sectors for cancer treatment are the key factors that drive the growth of the market. In addition, an increase in product approval is the key factor that is anticipated to drive the growth of the market in upcoming years. For instance, in November 2020, European Union (EU) approved Lynparza treatment with bevacizumab for homologous recombination deficient (HRD)-positive advanced ovarian cancer. In addition, the surge in cancer awareness and early screening of cancer also contribute to the growth of the Gynecological Cancer Drugs Industry. However, the high cost involved in new drug development coupled with the threat of failure & adverse effects associated with gynecological cancer drugs therapies poses to restrain the growth of the gynecological cancer drugs market. Conversely, the high potential of emerging economies and a higher number of potential drugs in the pipeline are the Gynecological Cancer Drugs Market Opportunity.Â
The Gynecological Cancer Drugs Industry is segmented by therapeutic modality, indication, and region. By therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Therapeutic Modality Segment Review
Gynecological Cancer Drugs Market
By Therapeutic ModalityThe targeted therapy segment is expected to lead the market throughout the forecast period.
Depending on therapeutic modality, the market is divided into chemotherapy, targeted therapy, and hormonal therapy. The targeted therapy generated the highest revenue in 2020. Owing to the adoption of target therapy across the world, targeted therapy offers many advantages as it interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes, which stop the growth of various types of cancers. Major factors that influenced the gynecology cancer drugs market growth include the fewer adverse effects of the therapy and the availability of a number of targeted therapeutics.Â
Indication Segment Review
Gynecological Cancer Drugs Market
By IndicationThe cervical cancer segment is expected to lead the market throughout the forecast period.
By indication, the indications segment is categorized into uterine cancer, ovarian cancer, vaginal & vulvar cancer, and cervical cancer. The cervical cancer segment dominated the market in 2020, and this trend is expected to continue during the forecast period. As HPV is the major causative agent for cervical cancer, thus HPV vaccine is used in most of the developed regions of the world for the prevention against the disease.
Region Segment Review
Region-wise, North America dominated the Gynecological Cancer Drugs Market Share in 2020 and is expected to be dominant during the forecast period, owing to the presence of large patient population, strong presence of key players, ease of drug availability, well-developed healthcare infrastructure, favorable reimbursement policies in the healthcare system, arise in research and development, & innovation activities and higher adoption of advanced therapeutics. However, Asia-Pacific is expected to grow at the highest CAGR, owing to an increase in the number of cancer-affected populations and a rise in awareness related to different cancers.
The major companies profiled in this report include Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.
Gynecological Cancer Drugs Market Report Highlights
Aspects | Details |
---|---|
By Indication |
|
By Therapeutic Modality |
|
By Region |
|
Key Market Players | APOTEX INC, TEVA PHARMACEUTICAL INDUSTRIES LTD, GLAXOSMITHKLINE PLC, NOVARTIS AG, MERCK & CO., INC, BRISTOL-MYERS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD, ASTRAZENECA PLC, PFIZER INC, ELI LILLY AND COMPANY |
According to the CXOs, the adoption of gynecological cancer drugs is expected to increase in the near future, owing to a high prevalence rate of gynecological cancers globally. The gynecological cancer drugs market has piqued the interest of healthcare providers owing to continuous R&D in the field of oncology drugs.This has led to the emergence of new treatment options for patients suffering from cancer. In addition, increase ininvestment from various organizations for cancer treatment and surge in risk factors that further drive the market growth.
According to the perspective of CXOs, North America is expected to dominate the global gynecological cancer drugsmarket during the forecast period, followed by Europe. In addition, Asia-Pacific and LAMEA are expected to offerlucrative opportunities to market players throughout the forecast period.
A. The total market value of the Gynecological Cancer Drugs market is $11,622.5 million in 2020
A. $21,791.44 million is the estimated industry size for Gynecological Cancer Drugs in 2030
A. The upcoming trends of the Gynecological Cancer Drugs Market are high incidence of gynecological cancers, growth in the importance of targeted drug therapies, an increase in investment from government, public, &private sector for cancer treatment, and a surge in the number of product approval for gynecological cancer drugs drive the market growth
A. North America is the largest regional market for Gynecological Cancer Drugs
A. Apotex Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG are the top companies to hold the market share in Gynecological Cancer Drugs
Start reading instantly.
This Report and over 66,905+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers